Published in J Gen Intern Med on December 01, 1998
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med (2006) 1.62
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J (2014) 1.26
Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health (2011) 0.88
Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med (2013) 0.85
Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. Diabetes Care (2010) 0.80
Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease. J Am Heart Assoc (2015) 0.79
Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey. BMJ Open (2015) 0.75
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
An updated coronary risk profile. A statement for health professionals. Circulation (1991) 11.71
Probability of stroke: a risk profile from the Framingham Study. Stroke (1991) 10.14
Markov models in medical decision making: a practical guide. Med Decis Making (1994) 8.14
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health (1987) 6.21
Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42
Incorporating patients' preferences into medical decisions. N Engl J Med (1994) 4.21
A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA (1991) 3.67
Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA (1995) 3.21
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet (1991) 3.02
Aspirin as an antiplatelet drug. N Engl J Med (1994) 2.72
Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke (1993) 2.44
Secular trends in stroke incidence and mortality. The Framingham Study. Stroke (1992) 2.07
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ (1993) 2.03
Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology (1994) 1.97
Effect of gender on long-term outcome of angina pectoris and myocardial infarction/sudden unexpected death. JAMA (1993) 1.92
Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis (1987) 1.86
Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med (1997) 1.68
Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology (1993) 1.47
Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation (1993) 1.23
Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making (1993) 1.09
Trends in mortality, morbidity, and risk factor levels for stroke from 1960 through 1990. The Minnesota Heart Survey. JAMA (1992) 0.96
Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making (1993) 0.93
DEALE-ing with life expectancy and mortality rates. Med Decis Making (1989) 0.92
Aspirin and other platelet-active drugs. The relationship between dose, effectiveness, and side effects. Chest (1992) 0.81
Patient preferences for nonsteroidal antiinflammatory drug related gastrointestinal complications and their prophylaxis. J Rheumatol (1993) 0.79
Changes in survival following stroke in five North Carolina counties observed during two different periods. Stroke (1989) 0.79
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract (1992) 2.97
Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. BMJ (1999) 2.87
A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med (1999) 2.68
Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm (1994) 2.42
Prostate cancer screening: a decision analysis. J Fam Pract (1995) 2.29
Ethnic and sex bias in primary care screening tests for alcohol use disorders. Ann Intern Med (1998) 2.26
Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? J Fam Pract (1999) 2.18
Care of adults with type 2 diabetes mellitus. A review of the evidence. J Fam Pract (1998) 2.04
Alcohol use disorders, consumption patterns, and health-related quality of life of primary care patients. Alcohol Clin Exp Res (1997) 1.76
The future of family medicine: clinical practice. J Fam Pract (2001) 1.73
Preferences of husbands and wives for prostate cancer screening. Arch Fam Med (1997) 1.71
Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol (1998) 1.53
Prostate cancer screening--what's a physician to do? Am Fam Physician (1997) 1.49
A cost-effectiveness analysis of epoetin usage for patients with AIDS. Pharmacoeconomics (1993) 1.39
BACH1 is a DNA repair protein supporting BRCA1 damage response. Oncogene (2006) 1.29
The Alcohol Use Disorders Identification Test (AUDIT) as a screen for at-risk drinking in primary care patients of different racial/ethnic backgrounds. Addiction (1997) 1.26
Dyspnea in cancer patients. Etiology, resource utilization, and survival-implications in a managed care world. Cancer (1996) 1.22
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass. Oncogene (2010) 1.10
Fluorescence spectroscopy for diagnosis of squamous intraepithelial lesions of the cervix. Obstet Gynecol (1999) 1.07
Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer (2001) 1.02
Patient factors influencing variation in the use of preventive interventions for alcohol abuse by primary care physicians. J Stud Alcohol (1996) 1.00
Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery (2001) 0.99
Item bias in the CAGE screening test for alcohol use disorders. J Gen Intern Med (1997) 0.98
Decision-aids for prostate cancer screening. J Fam Pract (2000) 0.96
Population-based time preferences for future health outcomes. Med Decis Making (2000) 0.96
Physicians' risk attitudes, laboratory usage, and referral decisions: the case of an academic family practice center. Med Decis Making (1991) 0.95
Screening for squamous intraepithelial lesions with fluorescence spectroscopy. Obstet Gynecol (1999) 0.93
Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum (2000) 0.93
Family practice in the tropics. Fam Med (1987) 0.92
Impact of spirometry on the management of chronic obstructive airway disease. J Fam Pract (1983) 0.92
Family medicine in Argentina. Fam Med (1987) 0.91
Identifying risk factors for imminent death in cancer patients with acute dyspnea. J Pain Symptom Manage (2000) 0.88
Performance estimation of diagnostic tests for cervical precancer based on fluorescence spectroscopy: effects of tissue type, sample size, population, and signal-to-noise ratio. IEEE Trans Biomed Eng (1999) 0.88
Controlling blood glucose levels in patients with type 2 diabetes mellitus. An evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association. J Fam Pract (2000) 0.82
A pilot study for a screening trial of cervical fluorescence spectroscopy. Int J Gynecol Cancer (2004) 0.81
The relationship between hemodynamics and inflammatory activation in women at risk for preeclampsia. Obstet Gynecol (2001) 0.81
Poliovirus vaccine options. Am Fam Physician (1999) 0.81
Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol (2000) 0.80
A glossary of medical decision-making terms. Prim Care (1995) 0.80
Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer (2002) 0.79
Cost-effectiveness analysis of screening health care workers for HIV. J Fam Pract (1994) 0.77
Warning patients about alcohol abuse. JAMA (1992) 0.75
Telephone interviews vs. workstation sessions for acquiring quality of life data. Proc AMIA Symp (1999) 0.75
Asymptomatic prostate nodules. J Fam Pract (1992) 0.75
Diagnosing sinusitis. Ann Intern Med (1993) 0.75
Two-way interactive videoconferencing: why bother? Fam Med (1998) 0.75
Cost-effectiveness and Down syndrome. Am J Public Health (1999) 0.75
Primary care for patients with type 2 diabetes. Moving beyond hyperglycemia. J Fam Pract (1998) 0.75
Documentation of referrals: recording bias due to patient insurance type. Fam Pract Res J (1990) 0.75
A statewide university hospital-based family medicine referral service. J Fam Pract (1986) 0.75
The medical school without walls: who will be the faculty? Tex Med (1995) 0.75
Faculty development for foreign teachers of family medicine. Fam Med (1997) 0.75
Predictive properties of serum prostate-specific antigen testing in a community setting. Arch Intern Med (1997) 0.75